About Cellenkos
Cellenkos is a company based in Houston (United States) founded in 2016 was acquired by China Cord Blood in April 2022.. Cellenkos has raised $15 million across 1 funding round from investors including China Cord Blood and BioVeda China Fund. Cellenkos operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, C4 Therapeutics, UCB and Erasca, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series A
Nov 04, 2021
-
Investors
China Cord Blood
& 1 more
-
Employee Count
Employee Count
-
Acquired by
China Cord Blood
(Apr 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Cellenkos
Cellenkos has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $15.0M
-
First Round
First Round
(04 Nov 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Series A - Cellenkos | Valuation | BioVeda China Fund |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cellenkos
Cellenkos has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include China Cord Blood and BioVeda China Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm funding companies in China and the US
|
Founded Year | Domain | Location | |
|
Biobanking services for umbilical cord blood stem cells are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cellenkos
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellenkos
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellenkos Comparisons
Competitors of Cellenkos
Cellenkos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, C4 Therapeutics, UCB and Erasca, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellenkos
Frequently Asked Questions about Cellenkos
When was Cellenkos founded?
Cellenkos was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Where is Cellenkos located?
Cellenkos is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Is Cellenkos a funded company?
Cellenkos is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series A of $15M, raised on Nov 04, 2021.
What does Cellenkos do?
The company was founded in 2016 in Houston, United States, within the biotechnology sector. Operations center on the creation of T-cell therapeutics targeting autoimmune and inflammatory conditions. Umbilical cord blood-derived T-regulatory cellular therapies are utilized to address immune dysfunction. The pipeline features CK0802 for infectious diseases, CK0801 for bone cancer, and CK0804 for myelofibrosis, supporting treatments in related medical areas.
Who are the top competitors of Cellenkos?
Cellenkos's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Cellenkos's investors?
Cellenkos has 2 investors. Key investors include China Cord Blood, and BioVeda China Fund.